ARTICLE | Company News
bluebird bio, Kite Pharma deal
June 29, 2015 7:00 AM UTC
Kite and bluebird partnered to develop and commercialize second-generation T cell receptor (TCR) candidates against HPV-16 E6 oncoprotein to treat HPV-associated cancers. The deal combines Kite’s TCR...